Androgen receptor (AR) transcriptional activity contributes to prostate cancer development and castration resistance. The growth and survival pathways driven by AR remain incompletely defined. Here, we found PDCD4 to be a new target of AR signaling and a potent regulator of prostate cancer cell growth, survival, and castration resistance. The 3 0 untranslated region of PDCD4 is directly targeted by the androgen-induced miRNA, miR-21. Androgen treatment suppressed PDCD4 expression in a dose responsive and miR-21-dependent manner. Correspondingly, AR inhibition dose-responsively induced PDCD4 expression. Using data from prostate cancer tissue samples in The Cancer Genome Atlas (TCGA), we found a significant and inverse correlation between miR-21 and PDCD4 mRNA and protein levels. Higher Gleason grade tumors exhibited significantly higher levels of miR-21 and significantly lower levels of PDCD4 mRNA and protein.
Introduction
Prostate cancer is the most frequent urological malignancy and a leading cause of cancer-related death in men worldwide (1) . There are over 160,000 estimated new cases of prostate cancer in the United States in 2018, with more than 29,000 predicted deaths (2) . Androgen deprivation therapy (ADT) is widely utilized as a standard treatment for locally advanced and metastatic prostate cancer (3) . Although many patients initially respond to ADT, they almost invariably relapse and develop castration-resistant prostate cancer (CRPC), often through the reactivation of androgen receptor (AR) signaling (4, 5) . CRPC eventually causes cancer-related death, even after life-prolonging therapies such as cabazitaxel, sipuleucel-T, abiraterone, enzalutamide, and Ra-223 (6) . Thus, there is a need to identify mechanisms of AR-induced tumor growth and castration resistance, and to establish new therapeutic targets and strategies for the treatment of CRPC.
miRNAs are a class of noncoding RNA that posttranscriptionally suppress gene expression through seed-pairing interactions with specific messenger RNAs (mRNAs; ref. 7) . miR-21 (hsa-miR-21-5p, miR-21) is a well-recognized and cancer-associated miRNA with proven oncogenic activity (8) . Levels of miR-21 are frequently elevated in most carcinomas, when compared with nonmalignant tissue, including in prostate cancer and CRPC (9) (10) (11) . Several cancer-related pathways, including AP-1, RAS, IL6, and TGFb, induce the expression of miR-21 (12) (13) (14) (15) . We previously discovered that the activated AR also directly induces miR-21 transcription, and that elevated miR-21 expression enhances androgendependent prostate cancer growth and is sufficient to drive CRPC cell growth (16) . However, the mechanisms of miR-21-mediated castration resistance remain undefined.
In this study, we examined several miR-21 target genes as potential regulators of prostate cancer growth. We found one target, PDCD4 (17, 18) , to be a potent suppressor of prostate cancer growth and survival. Our results show that androgen signaling suppresses PDCD4 expression, through miR-21, and that PDCD4 knockdown enhances cell proliferation, reduces apoptosis, augments tumorigenesis, and drives castration resistance. We also found that localized, high Gleason grade prostate cancer exhibits low levels of PDCD4 expression and high levels of miR-21 expression. These results implicate PDCD4 as a potential regulator of prostate cancer aggressiveness and therapeutic resistance.
Materials and Methods

Reagents and chemicals
Methyltrienolone (R1881; PerkinElmer) was dissolved in ethanol and bicalutamide (Sigma-Aldrich) was dissolved in DMSO and stored at À20 C. pCMV6-XL5-PDCD4 (SC111794) was purchased from OriGene Technologies Inc. pCMV6-EV was generated by PDCD4 removal and self-ligation. FlexiTube siRNA were purchased from Qiagen. Details of siRNAs, shRNAs, plasmids, and miRNAs are provided in Supplementary  Table S1 .
Cell culture
LNCaP and HEK 293 cells were purchased from ATCC. LAPC4 cells were provided by Dr. John Isaacs (Johns Hopkins Medicine, Baltimore, MD). All cell lines were authenticated using the Power Plex 16 HS System (Promega Corporation) and routinely verified to be Mycoplasma free. Cell cultures were maintained at 37 C in 5% CO 2 .
Reporter plasmids
The 3 0 UTR regions of miR-21 targets were amplified from HEK 293 genomic DNA (human embryonic kidney cells) by PCR. Primer sequences are provided in Supplementary Table S2 . PCR products were inserted into either the SpeI and HindIII or SacI and PmeI cloning sites of the pMIR-REPORT luciferase expression reporter vector (Ambion) to generate pMIR-UTR and mutant pMIR-UTR. The miR-21 reporter control consists of four perfect miR-21-binding sites cloned into the 3 0 UTR region of the pMIRreport vector.
Dual luciferase reporter assays
HEK 293 cells grown in 96-well plates were transfected with 25 nmol/L hsa-miR-21 mimic or negative control mimic, 100 ng luciferase-UTR reporter plasmid, 10 ng of reference pRL-CMV Renilla reporter plasmid, and OPTI-MEM to give a final volume of 100 mL. Luciferase activity was assayed 24 to 48 hours posttransfection using the dual luciferase assay and a Wallac Microbeta Luminometer. Firefly luciferase activity was normalized by Renilla luciferase. In each case, quadruplicate experiments were performed in parallel and repeated at least three to nine times.
Transfection and androgen treatment or inhibition
Transient transfections applied 20 nmol/L of miRNAs, miRNA inhibitors, or siRNAs, or plasmid vector (100 ng for 96 well, 1,000 ng for 6 well), using Lipofectamine 2000 (Invitrogen). To modulate androgen signaling, cells were grown or treated in complete medium (CM), consisting of RPMI 1640 with 10% FBS, or androgen-depleted medium (ADM), consisting of phenol red-free RPMI 1640 media supplemented with 10% charcoal-stripped serum (GE Healthcare Life Sciences). AR activation was achieved with R1881 and AR inhibition was achieved with bicalutamide (Sigma-Aldrich).
Cell proliferation analysis
Transiently transfected or stable cells were plated 48 hours after transfection into different media conditions (CM, ADM, 10 mmol/ L of bicalutamide). Cell viability was evaluated by MTS assay (Promega) 7 days after plating, or by MLuc Cell Viability Assay, as described previously (19) .
Gene expression analysis
Clinical parameters, Illuminahiseq_mirnaseq-miR_gene_expression, Mda_rppa_core-protein_normalization, and Illumina-hiseq_rnaseqv2-RSEM_genes_normalized data were downloaded from the TCGA data version 2016_01_28 for PRAD through The Broad Institute TCGA GDAC Firehose (20) . The correlation between the normalized expression of PDCD4 mRNA, PDCD4 protein, and hsa-miR-21 were determined by Patient Sample ID, and association with radical prostatectomy Gleason Score by Patient ID.
Western blot analysis
Cells were lysed in RIPA (Sigma-Aldrich) lysis buffer and extracts separated by SDS-PAGE and transferred onto nitrocellulose membranes. Membranes were blocked with Odyssey blocking buffer overnight at 4 C with antibodies against PDCD4 (1:1,000, D29C6, Cell Signaling Technology), c-Myc (1:1,000, Y69, Abcam), Cyclin E1 (1:1,000, HE12, Cell Signaling Technology), ACTB (1:10,000, AC-15, Sigma-Aldrich), and GAPDH (1:10,000, G9545, Sigma-Aldrich). Proteins were detected by IRDye secondary antibody (LI-COR) at room temperature for approximately 1 hour. Images were analyzed with the Odyssey Infrared Imaging System (LI-COR). Signals for each protein were normalized to ACTB or GAPDH.
Reverse transcription and qPCR
Total RNA was isolated with TRIzol reagent (Invitrogen). cDNAs were synthesized with 1 mg RNA using the QuantiTect Reverse Transcription Kit (Qiagen). qPCR applied 1 mL diluted cDNA (1:10), The SYBR GreenER qPCR SuperMix for ABI PRISM Instrument (Invitrogen), ABI Prism 7900HT (Applied Biosystems). The primer sequences of each gene are shown in Supplementary Table S2 .
Generation of stable cell lines
To generate stable PDCD4 knockdown cell lines, cells were transduced with lentiviral supernatants of pLKO.1-nontarget shRNA control or pLKO.1-shPDCD4 ( Supplementary Table S1 ) and selected by 2 mg/mL puromycin.
Flow cytometry
For cell-cycle analysis, cells were incubated in CM or ADM for 72 hours and trypsinized. Cells were fixed with 70% ethanol overnight at 4 C. Fixed cells were washed twice with cold PBS and incubated with 100 mg/mL RNase A and 50 mg/mL propidium iodide (PI) at 37 C for 1 hour. Samples were analyzed on the S3e Cell Sorter (Bio-Rad) and cell-cycle distribution was determined using the FlowJo software. Detection of apoptotic cells was performed using the Annexin V Apoptosis Detection Kit (Invitrogen). Cells were treated with different media conditions (CM, ADM) for 72 hours, and harvested and washed with cold PBS, incubated with Annexin V-FITC, and propidium iodide in the dark at room temperature for 15 minutes, and analyzed by flow cytometry.
Tumor xenografts
Animal studies were performed according to the protocols approved by the Animal Care and Use Committee at Johns Hopkins University (Baltimore, MD). Six-week-old male athymic nu/nu mice (Charles River Laboratories Inc.) were inoculated subcutaneously in the right dorsal flank with 5 Â 10 6 cells. Cells were suspended in equal volumes with Matrigel (Corning). Surgical castration was performed through bilateral orchiectomy at average tumor volume of 350 mm 3 for LNCaP or 380 mm 3 for LAPC4. Tumors were measured every other day and tumor volume (mm 3 ) was calculated by length Â width Â height Â 0.52.
Statistical analysis
The results are reported as the mean AE SD or SE. Statistical analyses applied GraphPad Prism. The differences between groups were evaluated by two-tailed, unpaired Student t test. Tumor volume over time was evaluated by two-way ANOVA with Bonferroni post test for each timepoint. P < 0.05 was considered statistically significant. Correlative expression was determined by Spearman correlation analysis and association with Gleason Score by one-way ANOVA and Bonferroni multiple comparison test.
Results
Identification of miR-21 target genes that mediate androgen independence
We examined seven previously identified miR-21 targets (ANKRD46, BCL7A, MAP2K3, MASPIN, MSH2, PDCD4, and RECK) as potential regulators of prostate cancer growth and castration resistance (16, 18, (21) (22) (23) (24) (25) (26) . The predicted miR-21binding regions for each gene transcript were subcloned downstream of the firefly luciferase gene to test for miR-21 regulation in 3 0 UTR reporter assays ( Fig. 1A , Top). A positive control 3 0 UTR reporter construct, miR-21 reporter, was engineered to contain four consecutive miR-21-binding sites. Each 3 0 UTR reporter was cotransfected into HEK 293 cells with miR-21 mimic, or control miRNA, and luciferase activity measured after 2 days. Six of the Screening for miR-21 target genes that promote prostate cancer growth and androgen independence. A, 3 0 UTR reporter analysis of reported miR-21 target genes. Top, Alignment of reported miR-21 target genes and miR-21-binding sites. Numbers indicate nucleotide site within mRNA. Bottom, HEK 293 cells were transfected with the 3 0 UTR report vector for each gene, miR-21 or control mimic, and reference Renilla luciferase. Luciferase activity is normalized to Renilla and relative to miR-control. Bars represent mean þ SE of at least five independent quadruplicate experiments. B, Androgen-dependent cell growth in CM as measured by MLuc Viability Assay, 7 days after miR-21 or siRNA transfection. C, Androgen-independent cell growth in ADM as measured by MLuc Viability Assay, 7 days after miR-21 or siRNA transfection. Growth is relative to control miRNA or control siRNA for each gene. Bars represent mean þ SE of two independent triplicate experiments. Ã , P < 0.05.
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Two separate siRNAs were then selected for each verified miR-21 target gene. Each siRNA was separately transiently transfected into the androgen-dependent cell line, LNCaP-MLuc. This cell line expresses secreted Metridia luciferase under the control of the b-actin promoter and enhancer, allowing noninvasive quantification of viable cell number over time by measuring relative MLuc activity in the conditioned media (19) . We measured the androgen-dependent growth of siRNA-transfected cells after 7 days in complete media (CM), which includes androgens from serum. Only one miR-21 target gene, PDCD4, showed enhanced androgen-dependent growth in CM when targeted by two different siRNAs ( Fig. 1B) . We also measured the effects of each siRNA on androgen-independent cell growth, in androgen-depleted media (ADM), where androgens were charcoal stripped from serum and phenol red was excluded from the media. Again, only one miR-21 target gene, PDCD4, drove androgen-independent growth when targeted by two different siRNAs (Fig. 1C) . These results implicate PDCD4 as a possible regulator of prostate cancer growth and castration resistance.
PDCD4 expression is suppressed by miR-21 and androgen receptor signaling
We then sought to study endogenous PDCD4 protein regulation in two established androgen-sensitive cell lines: LNCaP and LAPC4. Transient transfection with miR-21 mimics reduced PDCD4 protein expression in both cell lines by 30% to 40% ( Fig. 2A ). We then inhibited endogenous miR-21 by transfecting miR-21 inhibitors, which increased PDCD4 protein expression by 50% to 60%. PDCD4 expression was similarly suppressed by miR-21 mimics, and induced by miR-21 inhibitors, in normal prostate epithelial cells ( Supplementary Fig S1) . Understanding that the AR directly activates the miR-21 promoter (16, 27) , we hypothesized that androgen treatment would suppress PDCD4 protein expression. To test this, cells were grown in ADM for 24 hours and then treated with increasing levels of androgen (0.1-10 nmol/L R1881). As hypothesized, androgen treatment caused a doseresponsive decrease in PDCD4 protein expression in both LNCaP and LAPC4 cells ( Fig. 2B, left) . In a complementary experiment, cells were grown in CM for 24 hours and then treated with media containing decreasing levels of androgens (10-0.1 nmol/L R1881), or ADM. Androgen deprivation produced a doseresponsive increase in PDCD4 protein expression ( Fig. 2B, right) . Consistent with this, PDCD4 mRNA expression was elevated upon androgen deprivation, and PDCD4 mRNA expression was reduced by miR-21 mimic transfection ( Supplementary Fig. S2 ).
To further study PDCD4 suppression by AR signaling, we treated cells with the small-molecule AR inhibitor, bicalutamide. Bicalutamide treatment caused a dose-responsive increase in PDCD4 protein expression in both LNCaP and LAPC4 cell lines (Fig. 2C) . Finally, to determine whether androgens suppressed PDCD4 through endogenous miR-21, we transfected androgen-deprived cells with miR-21 inhibitors or control miRNA inhibitors, and then treated cells with androgen (10 nmol/L R1881). Consistent with the above results, androgen treatment suppressed PDCD4 protein expression in control-transfected cells by 40% to 50% (Fig. 2D , ADM Inhibitor-control vs. R1881 Inhibitor-control). However, Figure 2 . Androgen signaling suppresses PDCD4 expression through miR-21. A, LNCaP and LAPC4 cells were transfected with 20 nmol/L of miR-21 mimic or inhibitor for 48 hours and PDCD4 expression quantified by Western blot analysis, normalized to ACTB. B, Cells were grown in ADM for 24 hours and then stimulated with indicated amounts of androgen (R1881) or CM for 24 additional hours (left); or cells were grown in CM condition for 24 hours and then incubated with indicated concentration of R1881 or ADM for 24 hours (right). PDCD4 expression quantified by Western blot analysis, normalized to ACTB. C, Cells were incubated in CM for 24 hours, then treated for 24 hours with bicalutamide or vehicle control. PDCD4 expression quantified by Western blot analysis, normalized to ACTB. D, Cells were transfected with 20 nmol/L of miR-21 inhibitor or control. The next day cells were exposed to ADM, or ADM supplemented with 10 nmol/L R1881, for 24 hours. PDCD4 expression quantified by Western blot analysis, normalized to GAPDH. FC, fold change relative to control. E, Schematic of suppressed PDCD4 expression through androgen signaling and miR-21.
when miR-21 was blocked, androgens only suppressed PDCD4 expression by 10% to 20% (Fig. 2D , R1881 Inhibitor-control vs. R1881 miR-21-inhibitor). The miR-21 inhibitor did not affect PDCD4 expression in the absence of androgens. Collectively, these results indicate that androgens suppress PDCD4 expression in prostate cancer cells through miR-21 ( Fig. 2E) .
miR-21 and PDCD4 expression are inversely correlated in human prostate cancer and altered expression is associated with high tumor Gleason score
To determine the relationship between miR-21 and PDCD4 expression in human prostate cancer tissues, we performed Spearman correlation analyses using level 3 miRNA, mRNA, and protein expression data from The Cancer Genome Atlas (TCGA-PRAD; ref. 20) . PDCD4 protein levels were inversely correlated with miR-21 expression (Spearman r ¼ À0.18, P < 0.001) in 350 available matched patient samples (Fig. 3A) . The levels of PDCD4 mRNA were also inversely correlated with miR-21 expression (Spearman r ¼ À0.21, P < 0.0001) in the 546 available matched patient samples (Fig. 3B) . These correlations were similar in strength and significance when compared with those found for PDCD4 mRNA and PDCD4 protein (Spearman r ¼ 0.24, P < 0.0001; Fig. 3C ). We then examined the association of miR-21 and PDCD4 gene expression with radical prostatectomy Gleason score. PDCD4 mRNA and protein levels were significantly decreased in higher Gleason score tumors ( Fig. 3D and E, one-way ANOVA, P < 0.05), whereas the levels of miR-21 were significantly increased ( Fig 3F, P < 0.0001 ).
miR-21 induces androgen-dependent and androgenindependent growth through PDCD4 knockdown
To further study the role of miR-21 and PDCD4 in prostate cancer proliferation and castration resistance, we applied the same androgen-dependent cell lines, LNCaP and LAPC4, and a second cell proliferation assay, the MTS assay. We inhibited PDCD4 expression with two separate siRNAs, and we overexpressed PDCD4 with the pCMV6-PDCD4 vector. Western blotting analysis verified PDCD4 knockdown and overexpression in both cell models ( Supplementary Fig. S3 ). PDCD4 knockdown by both siRNAs significantly enhanced androgen-dependent growth in CM, when compared with si-control, in both cell lines ( Fig. 4A and B, CM, black bars). The level of growth induced by both PDCD4 siRNAs was comparable with that induced by miR-21 mimics. To study androgen-independent growth, cells were cultured in CM supplemented with bicalutamide ( Fig. 4 , dark gray bars) or in ADM ( Fig. 4 , light gray bars). Androgen deprivation, by bicalutamide or ADM, significantly decreased cell growth when compared with cells grown in CM. Notably, PDCD4 knockdown drove androgen-independent cell growth in both cell line models, either when AR was directly inhibited with bicalutamide ( Fig. 4A and B, dark gray bars) or when cells were grown in ADM ( Fig. 4A and B, light gray bars). The overall level of androgen-independent growth was similar in miR-21 mimic and PDCD4 siRNAtransfected cells. These results are consistent with the original siRNA screening experiments ( Fig. 1B and C) , and they support that PDCD4 knockdown is sufficient to drive androgen-independent prostate cancer growth. To determine whether miR-21 functioned through PDCD4 knockdown, we applied a PDCD4 expression vector that lacked the natural 3 0 UTR and corresponding miR-21-binding sites. The empty vector, pCMV6-EV, was applied as a negative control. Results demonstrate that PDCD4 overexpression significantly blocked miR-21-induced cell growth in androgen-containing CM ( Fig. 4C and D, black bars) . Importantly, PDCD4 overexpression also blocked the androgen-independent growth driven by miR-21 in bicalutamide-treated cells ( Fig. 4C and D, dark gray bars) and in cells grown in ADM ( Fig. 4C and D, light gray bars). In the absence of miR-21 overexpression (miR-control), elevated PDCD4 expression inhibited LAPC4, but not in LNCaP, cell growth under all treatment conditions ( Fig. 4C and D) . This decrease in LAPC4 cell growth was associated with an increase in Annexin V-positive cells, which was not similarly found in LNCaP cells (Supplementary Fig. S4 ).
PDCD4 knockdown induces cell-cycle progression and reduces apoptosis in a cell-specific manner
To expand upon the mechanism of PDCD4-mediated growth suppression, we generated two stable PDCD4 knockdown cell lines, LNCaP-shPDCD4 and LAPC4-shPDCD4, and we evaluated changes in cell proliferation and apoptosis. Corresponding negative control cell lines were generated with the shControl vector. Western blotting analysis demonstrated shRNA-mediated PDCD4 knockdown of 70% to 90% (Fig. 5A ). Both shPDCD4 cell lines demonstrated enhanced androgen-dependent growth and androgen-independent growth when compared with shControl cells (Fig. 5B) . In cell-cycle analyses, LNCaP-shPDCD4 cells exhibited a lower percentage of cells in G 1 phase and a larger percentage in S and G 2 -M phases, when compared with shCon-trol cells, in both CM and ADM conditions ( Fig. 5C ), suggesting that PDCD4 functions through cell-cycle regulation. However, surprisingly, LAPC4-shPDCD4 cells did not show the same changes in cell-cycle progression when compared with shControl cells ( Supplementary Fig. S5A ). Instead, LAPC4-shPDCD4 showed a significant decrease in the level of apoptosis when grown in CM and AD and compared with shControl cells (Fig.  5D ). This antiapoptotic effect of PDCD4 was not found in LNCaP-shPDCD4 cells ( Supplementary Fig. S5B ). Collectively, these results indicate a cell-specific response to PDCD4 knockdown, which includes enhanced proliferation and reduced apoptosis.
PDCD4 may regulate cell-cycle progression by inhibiting eIF4A, an RNA helicase and translation initiation factor. PDCD4 knockdown induced the expression of c-Myc and Cyclin E1, two eIF4A-regulated transcripts associated with cell-cycle progression (28, 29) , in LNCaP-shPDCD4 cells, but not LAPC4-shPDCD4 cells ( Supplementary Fig. S5C ). Furthermore, experiments are required to determine whether eIF4A is a key downstream target of miR-21 and PDCD4 in prostate cancer cells.
PDCD4 knockdown enhances prostate cancer tumorigenesis, tumor growth rate, and imparts castration resistance
To study the impact of PDCD4 knockdown on prostate cancer cell growth in vivo, we developed subcutaneous xenograft tumors using shPDCD4 and shControl cells in male athymic nude mice. Strikingly, the tumor take rate of LNCaP-shPDCD4 cells was considerably higher, when compared with LNCaP-shControl cells (90% vs. 60%, respectively). The onset of palpable tumor detection was also 7 days earlier for LNCaP-shPDCD4 cells, when compared with LNCaP-shControl tumors (Fig. 6A ). Furthermore, LNCaP-shPDCD4 tumors grew at a faster rate. When tumors PDCD4 knockdown induces androgen-dependent and androgenindependent prostate cancer growth. A and B, PDCD4 knockdown induced androgen-dependent and androgenindependent cell growth. LNCaP or LAPC4 cells were transiently transfected with 20 nmol/L of miRcontrol or miR-21 mimic, or 20 nmol/L of si-control or PDCD4 siRNAs. Fortyeight hours after transfection, cells were grown in CM, CM þ 10 mmol/L bicalutamide, or ADM for 7 days. Cell viability was evaluated by MTS assay and reported relative to miR-control signal in CM. Mean þ SE from 12 independent measurements. Ã , P < 0.05, relative to miR-control or sicontrol. C and D, Cells were cotransfected with miR-control or miR-21 mimic and pCMV6-empty vector (EV) or pCMV6-PDCD4. After 48 hours, cells were grown in CM, CM þ 10 mmol/L bicalutamide, or ADM for 7 days. Cell viability was evaluated by MTS assay and reported relative to miR-control signal in CM. Mean þ SE from 12 independent measurements ( Ã , P < 0.05).
PDCD4 Suppresses Prostate Cancer Growth and Castration Resistance www.aacrjournals.org reached an average volume of 350 mm 3 , mice were castrated by bilateral orchiectomy (Fig. 6, dashed line) . Castration markedly reduced LNCaP-shControl tumor growth, whereas LNCaP-shPDCD4 tumors continued to grow rapidly. This castrationresistant growth is most apparent when tumor growth is normalized to the time of orchiectomy (Fig. 6B ). In the stable LAPC4 cell line models, shPDCD4 tumors similarly showed earlier onset of tumorigenesis and enhanced tumor growth rate, when compared with shControl tumors (Fig. 6C ). The tumor take rate was also higher in LAPC4-shPDCD4 cells, when compared with LAPC4-shControl cells (70% vs. 50%, respectively). The impact of castration was less dramatic in LAPC4 cells, when compared with LNCaP cells, as has been experienced by others (30) . Nonetheless, LAPC4-shPDCD4 tumors grew significantly faster than LAPC4-shControl tumors after castration (Fig. 6D ). Collectively, these results demonstrate that reduced PDCD4 expression promotes prostate cancer tumorigenesis, tumor growth, and castrationresistant tumor growth.
Discussion
Despite the recent development of several new life-prolonging therapies (6) , CRPC remains an incurable disease. Improved CRPC treatment may come through a better understanding of the mechanisms capable of driving CRPC growth. Apart from the rare neuroendocrine phenotype, CRPC can be divided into two primary groups, those that are AR-dependent and those that are AR-independent. AR-dependent CRPC can develop through AR gene mutation, AR gene amplification, alternative AR splicing, aberrant AR cofactor activity, or anomalous androgen production (4) . Seeking pathways downstream of AR that are capable of causing castration-resistant growth, we identified miR-21 (16) . The activated AR directly induces the expression of the primary miR-21 transcript, pri-miR-21, by binding to the miPPR21 promoter as demonstrated by chromatin immunoprecipitation experiments and reporter assays (16, 27) . Several AR-independent pathways, including AP-1, RAS, IL6/STAT3, chromatin modification, and alternative polyadenylation of VMP1, can also induce the expression of miR-21 (12) (13) (14) 31) . Thus, there is potential for elevated miR-21 expression through AR-dependent or AR-independent signaling. Here, we sought to characterize pathways downstream of miR-21 that are capable of driving CRPC growth. Our results implicate PDCD4 suppression as a novel mechanism for enhanced prostate cancer tumorigenesis, tumor growth rate, and castration resistance.
PDCD4 (programmed cell death 4) originally acquired its name because it was found to be induced upon programmed cell death (32) . However, PDCD4 expression and function are not restricted to apoptosis. One important role of PDCD4 is as a posttranscriptional regulator of cap-dependent protein translation. PDCD4 binds and inhibits the eukaryotic translation initiation factor and RNA helicase, eIF4A (33) (34) (35) . It has been proposed that PDCD4 regulates gene transcripts with complex 5 0 UTRs through two possible mechanisms, by directly binding and sequestering eIF4A, and separately, by binding nuclear mRNAs and preventing their transfer to the cytoplasm (36) . Cap-dependent translation initiation, through eIF4A, regulates the expression of several cancer-associated genes, including c-Myc, cyclins, and PARP (28, 37, 38) . With this broad potential for gene regulation, PDCD4 inhibition can produce different phenotypic changes in different cell types (39) . Consistent with this, we found PDCD4 knockdown to induce proliferation in one model, LNCaP, and to inhibit apoptosis in another, LAPC4. In LNCaP cells, PDCD4 knockdown induced c-Myc and Cyclin E1 expression, possibly through enhanced eIF4A-mediated cap-dependent translation. Often, tumor-suppressive pathways can be flexible and dependent upon cell type, differentiation state, stress conditions, and active signaling pathways (40) . Although LNCaP and LAPC4 cells are both AR positive and androgen-sensitive, they differ in p53 and PTEN gene status (41, 42) . Further experimentation is needed to define the direct mechanism of PDCD4 in these and other prostate cancer cell lines.
Accumulating evidence suggests that PDCD4 is a true tumor suppressor. PDCD4-knockout mice develop spontaneous lymphomas (43) . Transgenic mice overexpressing PDCD4 produce significantly less tumors in the DMBA/TPA skin carcinogenesis model (44) . Here, for the first time, we reveal the role of PDCD4 in androgen-dependent prostate cancer cells and tumors. We find that reduced PDCD4 expression causes enhanced prostate cancer tumorigenesis, tumor growth rate, and castration resistance.
This study is also the first to report PDCD4 as an androgensuppressed protein, which occurs at least partially through miR-21 expression. Mitogen-induced S6K1 signaling and bTRCPmediated proteasome degradation can also lead to the rapid loss of PDCD4 protein levels (45) . Our data suggest that miR-21 is a dominant inhibitor of androgen-induced PDCD4 protein loss, because miR-21 inhibition rescued PDCD4 expression to 80% to 90% of basal levels following androgen treatment. It is notable that there is potential for cross-talk between these two pathways, because PTEN is a known miR-21 target, and PTEN suppresses the PI3K/mTOR/S6K pathway (46) . However, a large proportion of our studies were performed in the LNCaP cell line model, which is PTEN deficient. Additional studies are needed to distinguish the roles of AR, miR-21, PTEN, and PI3K/mTOR/S6K signaling in PDCD4 protein regulation in prostate cancer.
Previous studies have investigated the association of miR-21, and PDCD4, with aggressive features of localized prostate cancer. Elevated miR-21 expression is associated with poor biochemical recurrence-free survival and prostate cancer progression (47, 48) ; however, miR-21 levels alone may not provide substantially greater prognostic value beyond established clinical parameters such as Gleason Score or disease stage (49) . Reduced PDCD4 protein expression has similarly been associated with prostate cancer progression and aggressive pathologic features (50) . Our analyses of the TCGA-PRAD dataset provide a unique insight into miR-21, PDCD4 mRNA, and PDCD4 protein levels in the same human tumor samples. These results show significant, but weak, inverse correlation between miR-21 expression and PDCD4 mRNA and protein levels. There is also a clear association between elevated miR-21 miRNA, and reduced PDCD4 protein and mRNA, and advanced grade disease in TCGA samples. These trends are consistent with the tumor-suppressive nature of PDCD4 in LNCaP and LAPC4 cells. It is notable that PDCD4 expression values overlap in some samples among these disease states. Further detailed studies are needed to determine whether PDCD4 expression, or cellular localization, could provide new prognostic value for patients with localized disease.
In conclusion, we reveal PDCD4 as an androgen-suppressed protein. Androgen signaling inhibits PDCD4 expression through miR-21, and loss of PDCD4 expression induces prostate cancer proliferation and reduces cellular apoptosis. Loss of PDCD4 expression is sufficient to enhance tumorigenesis and to impart castration resistance in human tumor xenograft models. The miR-21/PDCD4 signaling pathway may represent a novel target for assessing or treating locally aggressive prostate cancer or metastatic CRPC.
